ELREXFIO 40 mg/ml, solution for injection bottle, 1.1 ml
Active ingredients: ELRANATAMAB
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injectionbottle, 1.1 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ELREXFIO 40 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 1,1 ml
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 22 Apr 2024
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65312065CIP75509830CIP133400955098300Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ELRANATAMABsolution | 40 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.